- •Compliance with biomarker blood tests performed every 4 months was high (83.2%).
- •Compliance with standard surveillance ultrasounds and CA 125 was significantly lower (51.9%).
- •Women who did biomarker testing every 4 months had lower stress scores at 12 months than at baseline.
We assessed the feasibility, patient acceptability of and compliance of a new surveillance strategy for ovarian cancer surveillance in women with BRCA mutations, based on assessments of serum CA125 and HE4 every 4 months (Risk of Ovarian Cancer Algorithm (ROCA) arm), compared to Standard of Care (SOC) surveillance with CA125 blood tests and pelvic ultrasounds every 6 months.
Women were recruited 6/13/16–9/11/17 from an integrated health care system in California for this non-randomized prospective cohort study. Women were invited to participate in a novel serum biomarker surveillance strategy using ROCA or they could opt to be in the standard of care control arm with ultrasound and CA 125 every 6 months. Outcomes assessed included compliance, self-reported distress using the Impact of Event Scale (IES) and cancer anxiety using the Cancer Worry Scale.
There were 159 women in the ROCA arm and 43 in the SOC arm. Overall, compliance was higher in the ROCA arm (83.2%) than in SOC (51.9%), p < 0.0001. Based on the IES, ROCA arm women reported less feelings about intrusion and avoidance at 12 months compared to baseline; the difference approached significance for intrusion (7.6% vs 4.1% severe, p = 0.057) and was statistically significant for avoidance (20.8% vs 9.9% severe, p = 0.034).
This pilot demonstrated that compliance was high with blood tests performed every four months for ovarian cancer surveillance. Moreover, ROCA women had lower stress scores over time than SOC women. Given the lack of clinical utility and poor compliance shown with traditional ultrasound and CA125 tests, further investigation is warranted of longitudinal biomarker surveillance for early detection of ovarian cancer.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- NCCN guidelines version 3-2019 genetic/familial high-risk assessment.
- Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?.Int. J. Cancer. 2009 Feb 15; 124: 919-923https://doi.org/10.1002/ijc.24038
- Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.J. Med. Genet. 2009 Sep; 46 (Epub 2008 Apr 15): 593-597https://doi.org/10.1136/jmg.2008.058248
- No efficacy of annual gynecological screening in BRCA1/2 mutation carriers; an observational follow-up study.Br. J. Cancer. 2007 May 7; 96 (Epub 2007 Apr 10): 1335-1342
- Surveillance of women at high risk for hereditary ovarian cancer is inefficient.Br. J. Cancer. 2006 Mar 27; 94: 814-819
- CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.Gynecol. Oncol. 2006 Jan; 100 (Epub 2005 Sep 26): 20-26
- Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.Maturitas. 2015 Mar; 80 (Epub 2014 Dec 30): 318-322https://doi.org/10.1016/j.maturitas.2014.12.009
- Risk management options elected by women after testing positive for a BRCA1 or BRCA2 mutation.Gynecol. Oncol. 2014 Feb; 132: 428-433https://doi.org/10.1016/j.ygyno.2013.12.014
- Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.JAMA Intern. Med. 2013 Jan 28; 173: 96-103https://doi.org/10.1001/2013.jamainternmed.962
- United Kingdom familial ovarian cancer screening study collaborators. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study.J. Clin. Oncol. 2017 May 1; 35 (Epub 2017 Feb 27): 1411-1420https://doi.org/10.1200/JCO.2016.69.9330
- Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – combined results from two screening trials.Cin Cancer Res. 2017 Jul 15; 23 (Epub2017 Jan 31): 3628-3637https://doi.org/10.1158/1078-0432.CCR-15-2750
- Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.Gene. 1999 Oct 1; 238: 375-385
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol. Oncol. 2008 Feb; 108: 402-408
- Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women.Gynecol. Oncol. 2012 Jun; 125 (Epub 2012 Mar 14): 667-672https://doi.org/10.1016/j.ygyno.2012.03.011
- Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers.J. Am. Stat. Assoc. 2001; 96: 429-439https://doi.org/10.1198/016214501753168145
- Impact of Event Scale: a measure of subjective stress.Psychosom. Med. 1979 May; 41: 209-218
- Psychological side effects of breast cancer screening.Health Psychol. 1991; 10: 259-267
- Changes in cancer worry associated with participation in ovarian cancer screening.Psychooncology. 2007 Sept; 16: 814-820
- Development of an ovarian cancer symptom index: possibilities for earlier detection.Cancer. 2007 Jan 15; 109: 221-227
- The FDA recommends against using screening tests for ovarian cancer screening: FDA safety communication.(September 7, 2016. Available at)https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm519413.htmDate accessed: September 8, 2016
- A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.Gynecol. Oncol. 2019 Sept; 19 (PMID:31500890): 31486-6https://doi.org/10.1016/j.ygyno.2019.08.034
- Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm.Gynecol. Oncol. 2012 Dec; 127 (Epub 2012 Aug 31): 556-563https://doi.org/10.1016/j.ygyno.2012.08.034
- Psychosocial factors associated with withdrawal from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) following one episode of repeat screening.Int. J. Gynecol. Cancer. 2015 Oct; 25: 1519-1525https://doi.org/10.1097/IGC.0000000000000507
Published online: March 04, 2020
Accepted: February 16, 2020
Received in revised form: January 22, 2020
Received: October 23, 2019
© 2020 Elsevier Inc. All rights reserved.